APTEVO THERAPEUTICS INC (APVO)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$1.74+1.75%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Broken: Primary pillar broken — Revenue growth stabilizes or improves: metric not reported.
Aptevo is developing new cancer treatments. It made good deals in 2026. Management improved by 13 points. The stock is cheap compared to peers.
Aptevo is losing money and revenue is expected to fall 60%. Earnings are negative and getting worse. The recent selloff shows investor doubts.
The price is about 50% below our fair value near $9. Analysts expect revenue to drop 60%. We see risk but also some value.
Breaks if: new large dilutive capital raise announced
Breaks if: EPS loss worsens beyond $24 per share in FY26
Breaks if: management confidence falls below 60
Breaks if: revenue decline exceeds 20% YoY in FY26
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently navigating a volatile management phase while focusing on advancing its clinical pipeline, particularly in oncology.
The market appears to have priced in a low valuation compared to peers, reflecting a justified but cautious stance. There is an expectations gap, indicating that investors may anticipate further challenges ahead.
Fundamentals are likely to remain under pressure in the near term due to a high probability of an earnings miss. However, management's focus on advancing key clinical programs may provide some stability if executed well.
The thesis hinges on the company's ability to meet clinical development milestones and the overall performance of the healthcare sector. Key triggers include guidance updates and the performance of sector bellwethers.
Over the next 1 to 3 years, APVO's performance will depend on its clinical progress and market conditions. Not investment advice.
The most important moves since the prior daily snapshot.
Valuation fell by 25.5 points (from 52.9 to 27.4).
Signal changed from 'mixed' to 'cautious'.
Our read on the company is unchanged since the prior snapshot.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.